C-Reactive Protein for Pulmonary Tuberculosis Screening and Treatment Response Monitoring in Children

Category	Detail
Condition	Pediatric pulmonary tuberculosis
Key Mechanisms	C-reactive protein (CRP) as an acute-phase protein marker for infection and inflammation
Target Population	Children ≤15 years presenting with symptoms suggestive of TB
Care Setting	Inpatient wards and outpatient TB and HIV clinics in Nairobi, Kenya

CRP diagnostic sensitivity for pediatric TB was suboptimal (35.5%–50.0%) at 5 mg/L cutoff.
Median CRP levels decreased significantly during TB treatment in children with confirmed or unconfirmed TB.
CRP elevation ≥5 mg/L at baseline identified 40% of children who showed treatment response via CRP decline.

CRP measurement alone has limited sensitivity and specificity for pediatric TB diagnosis.
Use CRP thresholds of 5 mg/L and 10 mg/L cautiously, considering low sensitivity.
Combine CRP with clinical and microbiological assessments for diagnosis.

Monitor CRP levels during TB treatment to assess treatment response, especially in children with baseline CRP ≥5 mg/L.
Follow national TB treatment guidelines for pediatric patients.

Serial CRP measurements can indicate treatment response with significant decreases near treatment end.
Monitor symptom resolution and anthropometric changes alongside CRP.

CRP is a nonspecific marker elevated in various infectious and inflammatory conditions.
Laboratory errors (e.g., reporting errors) can affect CRP result interpretation.

Kenyan children ≤15 years with suspected pulmonary TB

CRP levels decreased during treatment primarily in children with elevated baseline CRP, supporting its role in monitoring rather than diagnosis.

Use CRP as an adjunct biomarker rather than a standalone diagnostic tool in pediatric TB.
Interpret CRP results in the context of clinical presentation and microbiological findings.
Perform serial CRP testing to monitor treatment response, focusing on children with elevated baseline CRP.
Ensure quality control in CRP laboratory measurements to avoid reporting errors.
Obtain comprehensive clinical evaluation including chest radiography and microbiological testing.

Clinical Scorecard: Assessment of C-Reactive Protein as a Biomarker for Diagnosing and Monitoring Treatment in Pediatric Pulmonary Tuberculosis